Daily Management Review

CNBC: Bank of America spends over $250 million annually on weight-loss medications for employees


08/10/2026


Bank of America Corp., the second-largest U.S. bank by assets, allocates more than $250 million each year on GLP-1-based weight-loss drugs for its employees, Chief Executive Officer Brian Moynihan stated to CNBC.



CNBC: Bank of America spends over $250 million annually on weight-loss medications for employees
He said that four or five years prior, these costs were nonexistent, yet they signify a prudent investment in personnel.

"Our employees are significantly affected," the senior leader remarked, emphasizing the beneficial effects of these treatments on both immediate and prolonged health, including a lowered likelihood of heart disease.

Simultaneously, the bank, due to its scale, works to secure the most favorable prices with its partners, according to Moynihan.

BofA offers health coaching to assist employees in managing their weight and making lifestyle adjustments.

It allocates more than $2 billion each year for health care, indicating that these drugs make up about 13%. It has around 211,000 employees.

Medications based on GLP-1 consist of the well-known Ozempic and Wegovy from Danish company Novo Nordisk, along with Mounjaro and Zepbound from American firm Eli Lilly. The need for these drugs is increasing swiftly, and a month's supply may set you back several hundred dollars. Numerous employers in America are denying or restricting coverage for these expenses, according to CNBC.

source: cnbc.com